Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Authors
Keywords
-
Journal
eLife
Volume 5, Issue -, Pages -
Publisher
eLife Sciences Organisation, Ltd.
Online
2016-02-23
DOI
10.7554/elife.09462
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular mechanisms of drug resistance and its reversal in cancer
- (2015) Melis Kartal-Yandim et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- (2015) Claudia Allemani et al. LANCET
- Molecular pathways and therapeutic targets in lung cancer
- (2015) Emma Shtivelman et al. Oncotarget
- Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
- (2014) Akiko Murakami et al. PLoS One
- An open investigation of the reproducibility of cancer biology research
- (2014) Timothy M Errington et al. eLife
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
- (2013) T. Nakagawa et al. CANCER RESEARCH
- The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
- (2013) M-C Chen et al. Cell Death & Disease
- A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
- (2013) K E Ware et al. Oncogenesis
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- EGFR mutations in circulating tumour DNA
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
- (2011) Sonnemann ONCOLOGY REPORTS
- Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
- (2011) Giulia M. Stella et al. RESPIRATORY MEDICINE
- Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
- (2010) Ratika Krishnamurty et al. ACS Chemical Biology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started